ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008333/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the
efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib
in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal
growth factor receptor EGFR-activating mutation (s). Analyses of primary objective
(Progression Free Survival) will be done as defined in the protocol.
提供机构：
Vivli
创建时间：
2022-08-11
